Zika Breaking News

Zika breaking news brought to you by Zika News.

Sep 7, 2022 • 12:56 pm CDT
from Pixabay

Sweden-based TikoMed today announced an in vitro study examining the ability of the company's lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian), and Yellow Fever virus (vaccine strain YF17D).

In the non-peer-reviewed study published on September 2, 2022, ILB® potently inhibited infection by all the strains of Dengue, Zika, and Yellow Fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 μg/ml.

Professor Nicholas Barnes, Ph.D., Professor of Pharmacology & CEO, Celentyx Ltd, commented in a press release, "It is well recognized that infection by flaviviruses like Dengue, Zika, and Yellow Fever virus can lead to catastrophic, life-threatening conditions."

"This emphasizes the clinical need for safe and effective medicines to treat these infections."

"What I find particularly exciting about these results is the effects observed at ILB® concentrations achieved in humans following doses that have been well tolerated."

"These findings offer hope to the millions of patients that continue to be devastated by flavivirus infections."

While symptoms from Dengue, Zika, and Yellow Fever virus infection may be mild for some, they are severe and can be life-threatening.

Zika infection can have catastrophic consequences for pregnant women following the passing of the virus to their fetus with miscarriage or congenital disabilities, including microcephaly, that can be fatal.

As of September 7, 2022, the U.S. FDA has not approved a Zika vaccine.

Additional Zike vaccine news is posted at ZikaNews.com/Vaccine.

Note: This announcement was manually translated and curated for mobile readership.

Sep 1, 2022 • 5:33 am CDT
by Michal Jarmoluk

The Financial Times recently reported Gary Dubin, president of Takeda's global vaccine business, said one of the company's brightest prospects is for a vaccine targeting a mosquito-borne disease, the Zika virus.

Since 2016, Takeda has been collaborating with the U.S. government, which has agreed to supply up to $312 million in funding to the vaccine development program.

Takeda Pharmaceutical Company Limited announced that the Biomedical Advanced Research and Development Authority had selected Takeda's Vaccine Business Unit to develop a vaccine to support the Zika response in the U.S. and affected regions worldwide.

"Zika is another potentially vital vaccine to introduce from a public health perspective, and because the same mosquito transmits both dengue and Zika viruses, there are some natural synergies there," commented Dubin on August 29, 2022.

Takeda's TAK-426 (PIZV) is a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate.

On January 29, 2018, Takeda's Zika Vaccine candidate received U.S. FDA Fast Track Designation.

Aug 18, 2022 • 8:28 am CDT
U.S. CDC

The Zika virus outbreak in 2015 and 2016 left many children worldwide with devastating brain damage. The New York Times reported on August 16, 2022, how families and researchers find potential cures in the shadow of the COVId-19 pandemic.

About 25% of infected people may develop symptoms, but the illness is usually mild, with symptoms lasting between two and seven days.

However, there is scientific consensus that the Zika virus is a cause of microcephaly and Guillain-Barré syndrome, says the WHO/PAHO.

Microcephaly is a condition where a baby’s head is much smaller than expected.

During pregnancy, a baby’s head grows because the baby’s brain develops, says the U.S. CDC.

Microcephaly can occur because a baby’s brain has not developed properly during pregnancy or has stopped growing after birth, which results in smaller head size.

Furthermore, microcephaly can be an isolated condition, meaning that it can occur with no other significant congenital disabilities or in combination with other major birth defects.

And severe microcephaly is a more serious, extreme form of this condition where a baby’s head is much smaller than expected.

Severe microcephaly can result because a baby’s brain has not developed properly during pregnancy, or the brain started to develop correctly and then was damaged at some point during pregnancy.

As of August 17, 2022, there are no U.S. FDA-approved Zika vaccines.

However, several vaccine candidates are conducting clinical trials listed on this Zika News webpage.

Aug 5, 2022 • 11:20 am CDT
from Pixabay

The peer-review Journal of Infectious Diseases published a study on August 4, 2022, that the Zika virus (ZIKV) may remain active in men for months after infection.

While sexual transmission of ZIKV was confirmed in a recent epidemic, the mechanisms behind ZIKV persistence in the male reproductive tract are unknown.

Previously, researchers found that about 33% of men with symptomatic ZIKV infections shed ZIKV RNA in semen, and some men shed ZIKV RNA for over 3 months.

In this new study, the teachers evaluated the semen of 49 ZIKV-infected men to identify immune factors correlating with long-term ZIKV shedding in semen and ZIKV-infected cell types in semen.

They found prolonged ZIKV RNA shedding in semen was associated with male reproductive tract inflammation, indicated by higher leukocyte counts and inflammatory cytokine concentrations in the semen of long-term versus short-term shedders.

Additionally, they found ZIKV RNA in seminal leukocytes and epithelial cells.

These findings from ZIKV-infected men provide new critical insights into the impacts on male reproductive tract health.

As of August 5, 2022, the U.S. FDA has not approved any Zika vaccine candidates conducting clinical trials.

Note: This study's findings were manually curated for mobile readers.

Jun 21, 2022 • 4:15 pm CDT
Duke-NUS

Singapore-based Duke-NUS Medical School and Johnson & Johnson (J&J) jointly launched today a new J&J Satellite Center for Global Health Discovery that will drive new solutions to mitigate the threat posed by flaviviruses such as dengue and Zika. 

The Satellite Center at Duke-NUS is the first of the J&J Centers for Global Health Discovery to open in the Asia-Pacific region.  

Flaviviruses, like dengue and Zika, cause significant illness and death, yet no specific antiviral therapeutics are currently available.

Flaviviruses infect more than 400 million people each year, putting half of the global population at risk.

In particular, Asia bears nearly three-quarters of the global burden.

As Earth evolves, billions of people could be impacted in the coming decades as the animal vectors that carry flaviviruses venture beyond the tropical regions where they have traditionally thrived, spreading the diseases to new areas.  

"The establishment of the Satellite Center at Duke-NUS builds upon our strong track record in flavivirus research and bench-to-bedside innovations and will facilitate antiviral drug discovery for the prevention and treatment of flavivirus-associated diseases that are affecting communities in Southeast Asia and beyond."

"The collaboration is both timely and purposeful in realizing the School's vision of transforming medicine and improving lives," said Professor Patrick Casey, Senior Vice-Dean for Research at Duke-NUS, in a press statement issued on June 21, 2022.

Most recently, the School played a critical role in driving progress to tackle dengue by working with SingHealth’s Investigational Medicine Unit to conduct a Phase 2a clinical trial evaluating Janssen’s antiviral compound for the prevention and treatment of dengue.

As of June 21, 2022, the U.S. FDA had not authorized Zika prevention vaccines. 

Zika vaccine development news is posted at ZikaNews.com/Vaccines.

Note: This news was manually curated for mobile readership.

May 4, 2022 • 10:19 am CDT
by eveliendm

The World Health Organization (WHO) previously stated 'In India, ZIKV disease South-East Asian lineage has been detected in Gujarat, Madhya Pradesh and Rajasthan states in 2018.

Although Zika outbreaks are not unexpected, given the wide distribution of the primary mosquito vector, Aedes aegypti, and competent vector, Aedes albopictus, in Kerala and Maharashtra states, says the WHO.

In 2021, about 8,627 samples were tested, of which 152 were found positive for the Zika virus, reported local media.

However, the WHO considered the overall risk to be 'low' at the regional and global levels.

In contrast, the national level (Kerala and Maharashtra States) is currently assessed as 'moderate.'

Various travel advisories have been issued to notify international visitors of these areas.

On March 29, 2022, the U.S. CDC reissued an Alert - Level 2, Practice Enhanced Precautions, regarding the Zika outbreak in Uttar Pradesh, India.

The CDC Alert was initially published in December 2021.

The CDC previously issued Travel Alerts for COVID-19 and Dengue outbreaks in India.

These announcements were edited for clarity and manually curated for mobile readership.

Apr 4, 2022 • 3:12 am CDT
WHO

The World Health Organization (WHO) recently announced the launch of the Global Arbovirus Initiative, an integrated strategic plan to tackle emerging and re-emerging arboviruses with epidemic and pandemic potential.

The most common arboviruses are mosquito-borne illnesses, such as Dengue, Yellow fever, Chikungunya, and Zika.

Zika virus gained worldwide notoriety in 2016 when it was found to cause congenital disabilities such as microencephaly.

Zika remains a health threat in tropical and sub-tropical parts (map) and has been detected in about 89 countries.

"Arboviruses" might not be something most of us are familiar with. Still, they're a deadly threat to almost four billion people, so the UN health agency launched a plan on March 31, 2022, to prevent them from causing a new pandemic.

In a related press statement, Dr. Mike Ryan, head of the WHO's Emergency Programme, explained that the scheme would allow health authorities to tackle the "broad but related threats" posed by Dengue, Yellow fever, Chikungunya, and Zika.

"For each of these diseases, there have been gains in different aspects of surveillance response, research, and development," he said.

"But sustainability is often limited to the scope and duration and scope of disease-specific projects."

"There is an urgent need to re-evaluate the tools at hand and how these can be used across diseases to ensure an efficient response, evidence-based practice, equipped and trained personnel, and engagement of communities."

Furthermore, according to WHO data, Zika outbreaks could continue.

Information on Zika vaccine candidates is posted on this ZikaNew.com/vaccine page.

Note: This news article edited WHO information for clarity and was manually curated for mobile readers.

Feb 26, 2022 • 9:04 am CST

The peer-reviewed New England Journal of Medicine published a recent study from Brazil that found certain children born with congenital Zika syndrome (CZS) had a significantly greater mortality risk.

In this study published on Feb. 24, 2022, about 11 million live-born children were followed to 36 months of age.

The mortality rate was 52.6 deaths (95% confidence interval [CI], 47.6 to 58.0) per 1000 person-years among live-born children with CZS.

Compared with 5.6 deaths (95% CI, 5.6 to 5.7) per 1000 person-years among those without the syndrome. 

The burden of congenital anomalies, diseases of the nervous system, and infectious diseases as recorded causes of deaths were higher among live-born children with CZS than among those without the syndrome.

Additional Zika news is published on this weblink.

Feb 21, 2022 • 1:04 pm CST

The Zika virus continues to be a problem in many parts of the world and is often tough to detect. So when considering your next Caribbean travel destination, calculating your ability to protect yourself from mosquito bites is essential.

The Puerto Rico Department of Health Weekly Arboviral Diseases report indicates the Zika virus continues to infect people in 2022. 

The Report published on Feb. 14, 2022, shows (1) new 'probable' Zika cases confirmed in the San Juan, Puerto Rico vicinity.

These Zika cases are in addition to the (101) probable cases reported during 2021, with (10) near the city of San Juan.

The term "probable cases" is defined as infections with a positive serological test (IgM). 

Unfortunately, since Zika virus antibodies can persist for years after infection, serology cannot distinguish between a recent or past infection.

In the U.S., the Centers for Disease Control and Prevention (CDC) reported in 2020, there were (4) locally acquired Zika cases and (47) travel-related.

And none in 2021.

The CDC hosts a world map that displays Zika cases.

As of Feb. 20, 2022, the U.S. FDA has not authorized a Zika vaccine. However, several Zika vaccine candidates are conducting human clinical trials listed on this web page.

Feb 19, 2022 • 8:39 am CST

The ability of the Zika virus to cross the placental and blood-brain barriers to cause severe neurological disorders in developing fetuses makes the development of vaccines to prevent Congenital Zika Syndrome (CZS) an urgent global health priority, wrote researchers in a peer-reviewed study published by the journal NPJ Vaccines - Nature on Feb. 17, 2022.

In the current study, both prime and prime-boost vaccination with the ZPIV vaccine candidate provided 80% efficacy in protection against fetal malformations after ZIKV infection during pregnancy in C57BL/6 mice.

Importantly, neutralizing antibody titers correlated with protecting dams and fetuses against ZIKV infection.

ZPIV also is safe in healthy non-pregnant humans.

Because of its expected safety profile, inactivated virus vaccines, including ZPIV adjuvanted with aluminum hydroxide, would be a potentially favored platform for vaccinating pregnant women.

This aspect was not examined in the current study.

Further preclinical studies are necessary to investigate the efficacy of ZPIV vaccination during pregnancy.

Zika News publishes updated vaccine development news.

Jan 23, 2022 • 10:19 am CST

According to a new estimate published in U.S. CDC's Morbidity and Mortality Weekly Report (MMWR) on January 21, 2022, about 5% of U.S. infants born to mothers with a confirmed or possible Zika virus infection during pregnancy had a Zika-associated brain or eye defect.

This new study reconfirms a Zika virus infection during pregnancy can cause serious congenital disabilities of the brain and eyes, including intracranial calcifications, cerebral or cortical atrophy, chorioretinal abnormalities, and optic nerve abnormalities.

The frequency of these Zika-associated brain and eye defects, based on data from the U.S. Zika Pregnancy and Infant Registry (USZPIR), has been previously reported in aggregate.

Among 6,799 live-born infants in USZPIR born during December 1, 2015–March 31, 2018, 4.6% had any Zika-associated birth defect.

In a subgroup of pregnancies with a positive nucleic acid amplification test for Zika virus infection, the percentage was 6.1% of live-born infants.

The brain and eye defects most frequently reported included microcephaly, corpus callosum abnormalities, intracranial calcification, abnormal cortical gyral patterns, ventriculomegaly, cerebral or cortical atrophy, chorioretinal abnormalities, and optic nerve abnormalities.

About one-third of infants with any Zika-associated congenital disability had more than one defect reported.

And these brain and eye defects in an infant might prompt suspicion of prenatal Zika virus infection.

Moreover, among 325 pregnancies with laboratory evidence of confirmed or possible Zika virus infection that resulted in a pregnancy loss, 4% of fetuses had any reported Zika-associated congenital disability (C Moore, CDC, unpublished data, 2022).

These findings can help target surveillance efforts to the most common brain and eye defects associated with Zika virus infection during pregnancy should a Zika virus outbreak reemerge, and might signal the reemergence of Zika virus, particularly in geographic regions without ongoing comprehensive Zika virus surveillance.

The findings in this report are subject to at least five limitations. First, these data are based on information abstracted from medical records.

Although CDC provided specific guidance for evaluating all infants born from pregnancies with possible Zika virus exposure during pregnancy, these evaluations might not have been feasible, were not always conducted, or were not found in records.

Corresponding author: Nicole M. Roth, [email protected].

Dec 10, 2021 • 2:54 pm CST

The U.S. CDC announced on December 9, 2021, a new Level 2 Travel Advisory has been issued for the Zika outbreak in Uttar Pradesh, India.

Since October 2021, hundreds of Zika cases have been confirmed.

Zika is spread mainly through the bite of an infected mosquito. The types of mosquitoes that spread Zika bite people during the day and early evening.  

Moreover, travelers to Uttar Pradesh should take steps to prevent mosquito bites.

Zika can also be passed through sex from a person who has Zika to their sex partners. Therefore, not having sex eliminates the risk of getting Zika from sex.

Using condoms during sex can reduce the chance of getting Zika.

Zika can be passed from pregnant women to their fetuses, causing specific congenital disabilities, such as microcephaly. 

Furthermore, the CDC says pregnant women should NOT travel to areas with outbreaks of Zika. 

If visiting an area known for Zika transmission, the CDC recommends special precautions for pregnant women, the sex partners of pregnant women, and people considering pregnancy.

As of December 10, 2021, the U.S. FDA has not approved a Zika prevention vaccine.

Nov 17, 2021 • 1:20 pm CST

Japan-based Takada Vaccines, Inc. has scheduled a poster presentation for November 19, 2021, during the annual American Society of Tropical Medicine and Hygiene digital meeting.

This presentation, led by Erick Perez-Guzman, Mayuri Sharma, Ralph Braun with Takeda, will discuss how Zika virus-specific antibodies that can be distinguished from antibodies to other flaviviruses (FV), which will improve differential diagnosis and support the development of Zika vaccines in flavivirus-endemic regions''''Zika virus (ZIKV) re-emergence and spread into flavivirus endemic regions have caused serodiagnostic challenges due to antibody cross-reactivity among the FVs.

Currently, there are no viral envelope protein-based assays available to quantitatively measure ZIKV-specific antibody responses in individuals with prior FV exposure.

These presenters describe the development of a ZIKV-specific competitive microsphere-based immunoassay to support ongoing clinical trials of Takeda's purified inactivated ZIKV vaccine (PIZV) candidate.

The assay design allows ZIKV-specific antibodies present in plasma or serum samples to compete with the binding of an anti-ZIKV EDIII monoclonal antibody to a specific epitope on ZIKV virus-like particles coupled to Luminex magnetic microspheres. ZIKV-specific antibody levels in the presence or absence of antibodies to other FVs can then be determined in the samples.

Human and non-human primate (NHP) sample panels exposed to different FVs, including ZIKV, dengue virus (all four serotypes), Yellow Fever virus, Saint Louis Encephalitis virus, West Nile virus, Japanese Encephalitis virus, and Tick-Borne Encephalitis virus, were assessed using this assay.

The assay quantified ZIKV-specific antibodies in all presumptive or confirmed ZIKV or PIZV-immune samples, while all other FV-immune samples were negative in the assay.

Of note, the assay was also able to quantify PIZV-elicited ZIKV-specific antibodies in the presence of cross-reactive antibodies from prior FV vaccination.

In summary, these presenters say our data suggest that the assay can differentiate ZIKV-specific antibodies from antibodies to other FVs elicited by natural infection or vaccination.''

Availability of a ZIKV-specific antibody-based immunoassay will improve differential diagnosis, serosurveillance and support the development and implementation of ZIKV vaccines in FV endemic regions.

Takeda's Zika vaccine candidate (TAK-426; PIZV) is a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate conducting clinical studies.

Nov 8, 2021 • 3:45 pm CST

At least 89 people in Kanpur, India, have tested positive for the Zika virus, reported India.com. As a result, an alert has been issued, and the local authorities have launched a massive vector control drive to curb the spread of infected mosquitoes.

Dr. Nepal Singh, chief medical officer of Kanpur district in India's most populous state of Uttar Pradesh, told Reuters on November 8, 2021, "There has been a surge in cases of the Zika virus."

"The health department has formed several teams to contain the spread."

According to media reports, Health teams had recently collected blood samples of 525 people were sent to the virology lab of the King George's Medical University in Lucknow and the National Institute of Virology in Pune for testing.

The first Zika case in Kanpur was reported on October 23, 2021, when an Indian Air Force warrant officer tested positive for the virus.

Kanpur is located southeast of New Delhi in northern India and has about 2.9 million residents.

As of November 8, the U.S. FDA has not authorized a Zik preventive vaccine. However, several vaccine candidates are currently conducting clinical studies.

Oct 26, 2021 • 2:07 pm CDT

Though the number of Zika virus infections has decreased since 2018, scientists speculate they may be due to herd immunity in some areas.

However, there is still potential for future outbreaks.

Scientists want to understand how the human immune system recognizes the Zika virus to develop preventive vaccines.

Shannon Esswein, a graduate student, and Pamela Bjorkman, a professor at the California Institute of Technology, presented new insights on how the body’s antibodies attach to the Zika virus. These insights were published in PNAS, February 25, 2021.

To study the antibody response to Zika and other flaviviruses, Esswein and Bjorkman looked at several antibodies from the blood of patients from Mexico and Brazil.

To find antibodies that recognize flaviviruses, they used a piece of the outside of the virus, called the envelope domain III protein.

Previous studies have shown the envelope domain III is an essential target of protective antibodies that fight flavivirus infections.

The researchers studied how those antibodies changed over time as they mature and became better able to stick to the Zika virus and how the antibodies cross-react with other flaviviruses, including the four types of dengue viruses.

They found that the Zika antibodies also tightly stick to and defend against dengue type 1 and weakly stick to West Nile and dengue types 2 and 4.

“The weak cross-reactivity of these antibodies doesn’t seem to defend against those flaviviruses, but also doesn’t induce ADE,” Esswein said, suggesting envelope domain III may be useful to make a safe vaccine.

They also determined structures showing how two antibodies recognize Zika and West Nile envelope domain III.

Together, the team’s experiments show how the body mounts “a potent immune response to Zika virus,” says Esswein.

Their insights into the antibodies involved in this immune response will help inform vaccine design strategy.

As of October 26, 2021, the U.S. FDA had not approved a Zika vaccine.